Imaging Amyloid and Tau in the Retina: Current Research and Future Directions

Update Item Information
Title Imaging Amyloid and Tau in the Retina: Current Research and Future Directions
Creator M. Y. Tang; M. S. Blazes; C. S. Lee
Affiliation Wellesley College (MT), Wellesley, Massachusetts; Department of Ophthalmology (MB, CSL), University of Washington, Seattle, Washington; and Roger and Angie Karalis Johnson Retina Center (CSL), Seattle, Washington
Abstract The retina is a key focus in the search for biomarkers of Alzheimer's disease (AD) because of its accessibility and shared development with the brain. The pathological hallmarks of AD, amyloid beta (Ab), and hyper-phosphorylated tau (pTau) have been identified in the retina, although histopathologic findings have been mixed. Several imaging-based approaches have been developed to detect retinal AD pathology in vivo. Here, we review the research related to imaging AD-related pathology in the retina and implications for future biomarker research.
Subject Retina; Alzeheimer's Disease; pTau
OCR Text Show
Date 2023-06
Date Digital 2023-06
References 1. 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17:327-406. 2. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Translational Med. 2011;3:77sr1. 3. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer's disease. Lancet. 2021;397:1577-1590. 4. Alber J, Goldfarb D, Thompson LI, Arthur E, Hernandez K, Cheng D, et al. Developing retinal biomarkers for the earliest stages of Alzheimer's disease: what we know, what we don't, and how to move forward. Alzheimers Dement. 2020;16:229-243. 5. Aiello Bowles EJ, Crane PK, Walker RL, Chubak J, LaCroix AZ, Anderson ML, et al. Cognitive resilience to Alzheimer's disease pathology in the human brain. J Alzheimers Dis. 2019;68:1071-1083. 6. Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer's: exploring disease in the retina. Acta Neuropathol. 2016;132:767-787. 7. Yuan A, Lee CS. Retinal biomarkers for Alzheimer disease: the facts and the future. Asia Pac J Ophthalmol (Phila). 2022;11:140-148. 8. Jiang H, Wei Y, Shi Y, Wright CB, Sun X, Gregori G, et al. Altered macular microvasculature in mild cognitive impairment and Alzheimer disease. J Neuroophthalmol. 2018;38:292-298. 9. Wang X, Zhao Q, Tao R, Lu H, Xiao Z, Zheng L, et al. Decreased retinal vascular density in Alzheimer's disease (AD) and mild cognitive impairment (MCI): an optical coherence tomography angiography (OCTA) study. Front Aging Neurosci. 2020;12:572484. 10. Cheung CYL, Ong YT, Ikram MK, Ong SY, Li X, Hilal S, et al. Microvascular network alterations in the retina of patients with Alzheimer's disease. Alzheimers Dement. 2014;10:135-142. 11. Shi H, Koronyo Y, Rentsendorj A, Fuchs DT, Sheyn J, Black KL, et al. Retinal vasculopathy in Alzheimer's disease. Front Neurosci. 2021;15:731614. 12. Zhang J, Shi L, Shen Y. The retina: a window in which to view the pathogenesis of Alzheimer's disease. Ageing Res Rev. 2022;77:101590. 13. Ashok A, Singh N, Chaudhary S, Bellamkonda V, Kritikos AE, Wise AS, et al. Retinal degeneration and Alzheimer's disease: an evolving link. Int J Mol Sci. 2020;21:7290. 14. Sidiqi A, Wahl D, Lee S, Ma D, To E, Cui J, et al. In vivo retinal fluorescence imaging with curcumin in an Alzheimer mouse model. Front Neurosci. 2020;14:713. 15. Vandenabeele M, Veys L, Lemmens S, Hadoux X, Gelders G, Masin L, et al. The AppNL-G-F mouse retina is a site for preclinical Alzheimer's disease diagnosis and research. Acta Neuropathol Commun. 2021;9:6. 16. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54(suppl 1):S204-S217. 17. Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 1989;501:364-372. 18. Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017;2:93621. 19. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79:90-109. 20. Schön C, Hoffmann NA, Ochs SM, Burgold S, Filser S, Steinbach S, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One. 2012;7:e53547. 21. Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol. 2014;24:25-32. 22. Jiang J, Wang H, Li W, Cao X, Li C. Amyloid plaques in retina for diagnosis in Alzheimer's patients: a meta-analysis. Front Aging Neurosci. 2016;8:267. 23. Lee S, Jiang K, McIlmoyle B, To E, Xu QA, Hirsch-Reinshagen V, et al. Amyloid beta immunoreactivity in the retinal ganglion cell layer of the Alzheimer's eye. Front Neurosci. 2020;14:758. 24. Shi H, Koronyo Y, Rentsendorj A, Regis GC, Sheyn J, Fuchs DT, et al. Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. Acta Neuropathol. 2020;139:813-836. 25. den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. Acta Neuropathol Commun. 2018;6:147. 26. den Haan J, Morrema THJ, Rozemuller AJ, Bouwman FH, Hoozemans JJM. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: implications for in-vivo diagnostics. Acta Neuropathol Commun. 2018;6:75. 27. Dumitrascu OM, Lyden PD, Torbati T, Sheyn J, Sherzai A, Sherzai D, et al. Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline. Alzheimers Dement (Amst). 2020;12:e12109. 28. Dumitrascu OM, Rosenberry R, Sherman DS, Khansari MM, Sheyn J, Torbati T, et al. Retinal venular tortuosity jointly with retinal amyloid burden correlates with verbal memory loss: a pilot study. Cells. 2021;10:2926. 29. Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, et al. Feasibility study for detection of retinal amyloid in clinical trials: the anti-amyloid treatment in asymptomatic Alzheimer's disease (A4) trial. Alzheimers Dement (Amst). 2021;13:e12199. 30. Tadokoro K, Yamashita T, Kimura S, Nomura E, Ohta Y, Omote Y, et al. Retinal amyloid imaging for screening Alzheimer's disease. J Alzheimers Dis. 2021;83:927-934. 31. den Haan J, Hart de Ruyter FJ, Lochocki B, Kroon MAGM, Kemper EM, Teunissen CE, et al. No difference in retinal fluorescence after oral curcumin intake in amyloid-proven AD cases compared to controls. Alzheimer's Dement. 2022;14:e12347. 32. Dei Cas M, Ghidoni R. Dietary curcumin: correlation between bioavailability and Health potential. Nutrients. 2019;11:2147. 33. Kessel L, Lundeman JH, Herbst K, Andersen TV, Larsen M. Age-related changes in the transmission properties of the human lens and their relevance to circadian entrainment. J Cataract Refract Surg. 2010;36:308-312. 34. Mao X, Wang L. Recent advancements toward non-invasive imaging of retinal amyloid-beta for early detection of Alzheimer's disease. Neural Regen Res. 2022;17:1741. 35. Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, et al. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. Nat Commun. 2019;10:4227. 36. Lemmens S, Van Eijgen J, Van Keer K, Jacob J, Moylett S, De Groef L, et al. Hyperspectral imaging and the retina: worth the wave? Transl Vis Sci Technol. 2020;9:9. 37. More SS, Vince R. Hyperspectral imaging signatures detect Amyloidopathy in Alzheimer's mouse retina well before onset of cognitive decline. ACS Chem Neurosci. 2015;6:306-315. 38. More SS, Beach JM, Vince R. Early detection of Amyloidopathy in Alzheimer's mice by hyperspectral endoscopy. Invest Ophthalmol Vis Sci. 2016;57:3231-3238. 39. More SS, Beach JM, McClelland C, Mokhtarzadeh A, Vince R. In vivo assessment of retinal biomarkers by hyperspectral imaging: early detection of Alzheimer's disease. ACS Chem Neurosci. 2019;10:4492-4501. 40. Sharafi SM, Sylvestre JP, Chevrefils C, Soucy JP, Beaulieu S, Pascoal TA, et al. Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. Alzheimers Dement (N Y). 2019;5:610-617. 41. Lemmens S, Van Craenendonck T, Van Eijgen J, De Groef L, Bruffaerts R, de Jesus DA, et al. Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients. Alzheimers Res Ther. 2020;12:144. 42. Avila J, Jiménez JS, Sayas CL, Bolós M, Zabala JC, Rivas G, et al. Tau structures. Front Aging Neurosci. 2016;8:262. 43. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7:656-664. 44. Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, et al. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. J Alzheimers Dis. 2016;55:1083-1099. 45. Blennow K. Plasma pTau isoform assessment across disease stages. Alzheimers Dement. 2021;17:e050710. 46. Bucci M, Chiotis K, Nordberg A; for the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26:5888-5898. 47. Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:915-924. 48. Grimaldi A, Pediconi N, Oieni F, Pizzarelli R, Rosito M, Giubettini M, et al. Neuroinflammatory processes, A1 Astrocyte Activation and protein aggregation in the retina of Alzheimer's disease patients, possible biomarkers for early diagnosis. Front Neurosci. 2019;13:925. 49. Ho WL, Leung Y, Tsang AWT, So KF, Chiu K, Chang RCC. Review: tauopathy in the retina and optic nerve: does it shadow pathological changes in the brain? Mol Vis. 2012;18:2700-2710. 50. Yang J, Yang J, Li Y, Xu Y, Ran C. Near-infrared fluorescence ocular imaging (NIRFOI) of Alzheimer's disease. Mol Imaging Biol. 2019;21:35-43. 51. Cao KJ, Kim JH, Kroeger H, Gaffney PM, Lin JH, Sigurdson CJ, et al. ARCAM-1 facilitates fluorescence detection of amyloid-containing deposits in the retina. Transl Vis Sci Technol. 2021;10:5. 52. Habiba U, Descallar J, Kreilaus F, Adhikari UK, Kumar S, Morley JW, et al. Detection of retinal and blood Ab oligomers with nanobodies. Alzheimers Dement (Amst). 2021;13:e12193. 53. GlobeNewswire. Amydis receives NIH grant award to develop a novel tau retinal tracer for Alzheimer's diseases and other tauopathies, 2021. Available at: https://www.globenewswire. com/en/news-release/2021/09/02/2290749/37146/en/Amydis-Receives-NIH-Grant-Award-to-Develop-a-Novel-Tau-Retinal- Tracer-for-Alzheimer-s-Diseases-and-other-Tauopathies.html. Accessed July 28, 2022. 54. Sauer L, Komanski CB, Vitale AS, Hansen ED, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) in eyes with pigment epithelial detachments due to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2019;60:3054-3063. 55. Schmidt J, Peters S, Sauer L, Schweitzer D, Klemm M, Augsten R, et al. Fundus autofluorescence lifetimes are increased in non-proliferative diabetic retinopathy. Acta Ophthal. 2017;95:33-40. 56. Sadda SR, Borrelli E, Fan W, Ebraheem A, Marion KM, Harrington M, et al. A pilot study of fluorescence lifetime imaging ophthalmoscopy in preclinical Alzheimer's disease. Eye. 2019;33:1271-1279. 57. Yanagihara RT, Lee CS, Ting DSW, Lee AY. Methodological challenges of deep learning in optical coherence tomography for retinal diseases: a review. Transl Vis Sci Technol. 2020;9:11. 58. Hart de Ruyter FJ. Early tau phosphorylation as a potential retinal biomarker for AD and other tauopathies. Alzheimers Dement. 2020;16:e040924.
Language eng
Format application/pdf
Type Text
Publication Type Journal Article
Source Journal of Neuro-Ophthalmology, June 2023, Volume 43, Issue 2
Collection Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management © North American Neuro-Ophthalmology Society
ARK ark:/87278/s6s4wbp8
Setname ehsl_novel_jno
ID 2498916
Reference URL https://collections.lib.utah.edu/ark:/87278/s6s4wbp8
Back to Search Results